Vera Therapeutics
VERA
55 hedge funds and large institutions have $459M invested in Vera Therapeutics in 2022 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 25 increasing their positions, 9 reducing their positions, and 3 closing their positions.
178% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 9
133% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 3
66% more capital invested
Capital invested by funds: $276M → $459M (+$183M)
8% more funds holding
Funds holding: 51 → 55 (+4)
3.47% more ownership
Funds ownership: 76.19% → 79.66% (+3.5%)
20% less funds holding in top 10
Funds holding in top 10: 5 → 4 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IBT
International Biotechnology Trust
London,
United Kingdom
|
+$5.19M |
| 2 |
PAMP
Polar Asset Management Partners
Toronto,
Ontario, Canada
|
+$4.29M |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
+$3.17M |
| 4 |
EP
Eversept Partners
New York
|
+$2.92M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
+$2.27M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$2.46M |
| 2 |
OCA
Octagon Capital Advisors
New York
|
-$781K |
| 3 |
JP Morgan Chase
New York
|
-$442K |
| 4 |
Citigroup
New York
|
-$187K |
| 5 |
DTL
Dynamic Technology Lab
Singapore
|
-$162K |
VERA Hedge Fund Activity: Q3 2022 in Review
55 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Vera Therapeutics (VERA) for Q3 2022, worth a combined $459M — up 66% from $276M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new VERA positions and 3 closed out — a net gain of 4 holders — while 25 added to existing stakes and 9 trimmed.
The largest buyer was International Biotechnology Trust, adding an estimated $5.19M. The largest seller was Citadel Advisors, cutting an estimated $2.46M.
- 55 institutional investors held Vera Therapeutics (VERA) as of Q3 2022, up from 51 in Q2 2022.
- Funds reported $459M of Vera Therapeutics stock for Q3 2022, up 66% quarter-over-quarter.
- 7 funds opened new Vera Therapeutics positions in Q3 2022 and 3 closed out, a net change of +4 holders.
- The largest Vera Therapeutics buyer in Q3 2022 was International Biotechnology Trust, an estimated $5.19M added.
- The largest Vera Therapeutics seller in Q3 2022 was Citadel Advisors, an estimated $2.46M sold.
Based on aggregated 13F filings for Q3 2022.